Chris Stevo | SVP and Chief IR Officer |
Dr. Albert Bourla | Chairman and CEO |
Dave Denton | CFO |
Dr. Mikael Dolsten | Chief Scientific Officer and President, Pfizer R&D |
Angela Hwang | Chief Commercial Officer and President, Global Biopharmaceuticals Business |
Aamir Malik | Chief Business Innovation Officer |
Dr. Chris Boshoff | Chief Oncology R&D Officer |
Nicole Germino | Truist Securities |
Umer Raffat | Evercore |
Evan Seigerman | BMO |
Terence Flynn | Morgan Stanley |
Chris Shibutani | Goldman Sachs |
Louise Chen | Cantor |
Mohit Bansal | Wells Fargo |
Trung Huynh | Credit Suisse |
Colin Bristow | UBS |
Kerry Holford | Berenberg |
Geoff Meacham | Bank of America |
Tim Anderson | Wolfe Research |
Carter Gould | Barclays |
Steve Scala | Cowen |
David Risinger | Leerink Partners |
Andrew Baum | Citi |
Chris Schott | JPMorgan |
Rajesh Kumar | HSBC |
Michelle Rivera | inThought Research |
Good day, everyone, and welcome to Pfizer’s Second Quarter 2023 Earnings Conference Call. Today’s call is being recorded.
At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.